I don’t know where else you would find an investment bank with such expertise. They could move from financial and strategic discussions to highly scientific, clinical discussions with ease. In the end, they brought all these perspectives to bear, developing an exceptional strategy that created value for our company.
Outcome Capital has demonstrated an astute and insightful understanding of our value proposal and the major companies in the cardiovascular space. They provided us with invaluable strategic advice and I can’t think of better partners to have guided us through the process.
They understood our technology and business as well as anyone.
Outcome worked diligently with our executives and board to develop and communicate a strategy that was instrumental in enhancing the value of our company. Their business acumen and knowledge of our market space drove a complex transaction to a very successful close.
Advanced Uro-Solutions engaged the services of Outcome Capital late in the process of being acquired. Outcome Capital took control of all further negotiations and masterfully increased the value of our final offering. The added value Outcome Capital was responsible for was 10 times greater then the value we invested in their services. Our only regret was in not bringing them on sooner. Arnie and Oded brought an amazing team of talented, organized and highly effective individuals. We could NOT have been more satisfied.
From advances in personalized medicine and diagnostics to transformations in medical devices and healthcare IT — not only are avenues of patient care changing but also the financial landscape and fluid interplay between life science sectors.
The Outcome Capital Life Sciences team is dedicated to following the most recent scientific advancements as well as understanding their implications on market dynamics. The unmatched combination of scientific backgrounds and business acumen of Outcome professionals ensures they see the value of their clients’ businesses not only in today’s market but also the future potential enabling them to maximize value for their clients.
Outcome Capital is a trusted partner to middle-market companies providing M&A, capital raise and advisory services in life science markets.
Dr. Ben-Joseph is Managing Director with Outcome Capital, and co-lead of its life sciences and healthcare practice. He brings a unique combination of executive, entrepreneurial, scientific and transactional experience to Outcome Capital and is passionate about assisting cutting-edge life sciences companies in enhancing their strategic value and developing a path to successful liquidity.
Dr. Ben-Joseph also serves on the Board of Directors for life sciences companies: XableCath, a clinical stage medical device innovator developing cost-effective treatment options for peripheral and cardiovascular disease and KidneyCure, a regenerative medicine company developing novel cell-based therapies for the treatment of chronic renal disease. Before joining Outcome Capital, Dr. Ben-Joseph was Managing Director at Boston Equity Advisors, a boutique investment banking firm focusing on private equity and merger and acquisition in the therapeutic medical technology sector. Prior to that, Dr. Ben-Joseph was an Executive-in-Residence at Oxford Bioscience Partners, a life sciences venture capital firm, and CEO and co-founder of Caliber Therapeutics, a company engaged in the development of catheter-based drug delivery products for the intervention of atherosclerotic diseases. His past managerial and entrepreneurial positions also include President and CEO at Deep Vein Medical, an early stage medtech company dedicated to treating deep venous reflux in patients suffering from chronic venous insufficiency, President and CEO of X-Cell Medical, a clinical stage drug/device convergence company engaged in the development of novel stent-based anti-restenotic drugs, President of Ester Neurosciences, a clinical stage biotech company engaged in the development of novel compounds for the treatment of neurological diseases, and co-founder and CEO of Biolight Phototherapy, a company engaged in the development of laser-based medical devices for the treatment of dermatological disorders and allergies.
His academic appointments include Assistant Professor at the Departments of Radiology and Neuroscience at the University of Michigan, a Visiting Associate Professor at Tokushima University in Japan and a Visiting Scientist at Parke-Davis (Pfizer). Dr. Ben-Joseph has published numerous peer-review scientific papers as well as industry publications and has received numerous awards and scholarships.
Dr. Ben-Joseph graduated with Honors from Imperial College of Science, Technology and Medicine and received his Ph.D. from the University of Cambridge. He completed his post-doctoral training at the University of Michigan and received an MBA magna cum laude from the University of Bradford. He is a FINRA Registered Securities Representative holding Series 7, 63 and 79 and a Registered Securities Principal holding a Series 24.
Arnie Freedman is a Managing Director with Outcome Capital, and co-lead of its healthcare practice. Arnie has extensive experience in private equity financings, mergers and acquisitions and preferred securities. His primary focus is in life sciences offerings, including medical devices, diagnostics and drug development. Mr. Freedman assists companies with pre-IPO and early stage financings and prepares companies for the rigor required for merger and acquisition activity.
Mr. Freedman has been involved in the management of entrepreneurial businesses for over 25 years, previously as a co-founder and principal in Boston Equity Advisors, LLC, a registered broker-dealer and boutique investment-banking firm. In this company, Mr. Freedman focused on M&A transactions, private placements of debt and equity with institutional investors from the venture capital, private equity, family-foundation and hedge fund community. He uses his knowledge of the private placement process to help clients prepare for the scrutiny of potential investors by conducting a pre-financing review of client operations and corporate structure, recommending changes, assisting management in implementing those changes and preparing documentation investors require including business plans, marketing and insurance reimbursement strategies and financial models. Arnie brings his operating expertise to bear on the advice and counsel he provides to his clients.
Prior to Boston Equity Advisors, Mr. Freedman was the founder and CEO of Rustel, a Russian/American satellite telecommunications company, where he developed an extensive connection to the European investment community. He worked closely and collaborated with investment banking advisors Deutsche Morgan Grenfell, Salomon Brothers, and Creditanstalt International Advisors.
Mr. Freedman is a graduate with honors from the University of Massachusetts. He is a FINRA Registered Securities Representative holding a Series 7, 63 and 79 and a Registered Securities Principal, Series 24.
Arnie resides in Sharon, Massachusetts with his wife.
Dr. Manning is a Managing Director with Outcome Capital and manages its UK operations. He brings significant experience of the UK and European Capital markets, strong relationships within the European Life Science industry, entrepreneurial flair and a strong academic background to Outcome Capital. He is committed to enhancing the corporate and shareholder value of innovative life science companies.
Before joining Outcome Capital, Dr. Manning accrued over 25 years of international Life Sciences experience, including over 3 years as Founder and Managing Director of strategic and financial advisory firm, Akesios Associates. Shawn also spent over 12 years as a rated Equity Analyst with Dresdner Kleinwort Benson, SG-Cowen, Société Generale, and Singer Capital Markets, covering ‘Big Pharma’, speciality and emerging pharmaceutical, and biotechnology. Since 2005 Manning’s research supported over £500 million in new funding for Life Science companies. Before entering the City of London, Manning spent 5 years consulting to the pharmaceutical industry, and managing Datamonitor’s Healthcare practice. In this capacity he also worked alongside European, US and Japanese pharmaceutical companies, leading consultancy projects focusing primarily on strategic product positioning, including portfolio, opportunity and pricing analysis.
Manning holds a Doctorate degree from the University of Oxford (Hertford College), specialising in infectious disease and a BSc (Hons) and ARCS from Imperial College, London. He is a Fellow of the Royal Society of Medicine, a member of the Advisory Board for OBN, the UK’s largest Life Sciences industry network, and Chairman of OBN’s investment and tax Special Interest Group (itSIG).
Dr. Ellen S. Baron joins Outcome Capital bringing extensive experience in the private placement of securities for life science companies with deep domain expertise across multiple disciplines in pharmaceutical and biotechnology industries. Ellen is committed to the success of emerging growth companies bringing nearly 30 years of industry experience with proven deal execution and a unique access to the people, resources and markets that are vital for success. She has been involved in the raise of more than $150M of investment capital and has $2B in deals to her credit from her days in pharma and biotech.
Dr. Baron currently serves on the Board of Directors of Sixth Element Capital, a UK-based oncology focused venture capital fund and on the board of SFH, a Maine-based nutraceutical company.
Dr. Baron was most recently a Managing Director at Healthios Capital Markets, LLC, leading their firm’s biopharmaceutical practice. Prior to that she spent 9 years as Partner at Oxford Bioscience Partners, a Boston-based life science venture capital firm where she led numerous therapeutic and diagnostic investments within the $1 billion portfolio of 149 companies.
Ellen previously served as Senior Vice President, Business Development at Human Genome Sciences, a publically traded biopharmaceutical company where she was responsible for all business functions of the Company including corporate partnering, licensing and investor interface.
Ellen previously had spent 20 years at Schering-Plough Corporation in both Research and Development and Business Development. She has over 30 years of operating and investment expertise across the spectrum of the pharmaceutical and biotechnology industries, with particular emphasis in oncology, neurology, and infectious disease. Ellen holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate at the Public Health Research Institute in New York.
Dr. Don Haut brings a broad life-science business perspective to Outcome Capital from senior executive and Board positions in Strategy, M&A, and General Management, with deep domain expertise across multiple disciplines in pharmaceutical, biotech, and medical device industries. Don is an experienced transaction professional with over $4B in deals to his credit.
Dr. Haut is also Managing Director for Haut Capital and currently serves on the Board of Directors for three health care companies: MiMecore Therapeutics, Arthrosurface, and Xiros. Prior, he was Vice President for New Business Ventures at The Medicines Company, where he was responsible for leading that company’s deal to license Alnylam’s PCSK9 inhibitor. Previously, he was the Senior Vice President for Strategy and Business Development at Smith and Nephew’s Advanced Surgical Devices Division, where he was responsible for all strategy development, M&A and licensing activities, and also built and ran Smith & Nephew’s Women’s Health business. Dr. Haut also previously held similar roles at 3M, JSB Partners and McKinsey and Company.
Don obtained his MBA at Washington University’s Olin School of Business, his PhD in Molecular Biology at the University of Missouri-Columbia, and his undergraduate degree at the College of Wooster.
Eilon S. Amir is a Vice President at Outcome Capital and brings a unique combination of strategic and transactional expertise with over 15 years of experience in corporate strategy and finance, merger and acquisitions and business development in innovative life sciences companies.
Prior to joining Outcome Capital, Mr. Amir was a Director of Business Development/M&A at Merck/EMD Millipore where he worked on divisional transactions in collaboration with the Corporate Group M&A and Business Units. Prior to Merck/EMD Millipore, Mr. Amir was a Director of Corporate Development/M&A at Perkin Elmer where he was responsible for executing M&A and business development strategies for life science tools, analytics, and diagnostics.
Mr. Amir also held several positions in the investment banking industry including Senior Associate at Citigroup Corporate Finance/ Investment Banking focusing on technology companies and Associate at American Capital pursuing leveraged buyouts and private equity investments. Prior to American Capital, Mr. Amir spent four years with in the Merchant Banking and Commercial Finance Group at GE Capital. While at GE Capital, Mr. Eilon also participated in a joint venture between GE Capital and The Goldman Sachs Group, Inc.
He received his BA in Finance and Marketing from University of Wisconsin-Madison and Executive MBA degree from the Hebrew University in Jerusalem. He resides in Massachusetts with his wife and three children.
Craig is the Vice President of Life Sciences at Outcome Capital and brings corporate and commercial expertise in the diagnostic and life science space. A business leader with extensive global experience in the life sciences and healthcare industries, Craig has held various executive positions from start-up companies through large, well-established international corporations. His success building commercially viable and sustainable enterprises has lead to the completion of several successful acquisitions over the past several years including Caliper Life Sciences, HandyLab and BioHelix. In addition to his role as Vice President of Life Sciences at Outcome Capital, Craig also serves as a strategic advisor for bluDiagnostics, an early stage technology company based in Madison, WI. Craig also volunteers with mentoring activities for Women in Biotech and as an advisor to Springboard Enterprises.
Craig’s scientific background and business experience spans sales, marketing, business development, licensing, strategic partnerships and operations. His key successes include developing and launching new businesses at Fisher Healthcare, HandyLab, Becton Dickinson and Caliper Life Sciences within the diagnostic market space. Craig’s knowledge of the diagnostic and life science tools markets has allowed him to develop markets across the globe and leverage strategic partnerships to further market expansion for many of his clients.
Craig holds a Bachelor of Science from the University of Wisconsin – Madison and a Master of Science from Yale University. He resides in New Hampshire with his wife Krista and son Ben.
Thom joined Outcome Capital in May 2015 as an Analyst. Prior to this, Thom pursued his passion for the public and non-profit sectors by serving in multiple roles including Youth Development Program Director at the YMCA Cape Cod and English and History Teacher at the Southeast Alternative School.
Subsequently, Thom accepted a full academic scholarship to Suffolk University’s Sawyer Business School in Boston, where he completed his MBA. During this time Thom was elected President of the Suffolk University Graduate Business Association and served as class speaker for graduation.
Thom has held a Massachusetts Teaching License and graduated cum laude with a BS from Suffolk’s Honor’s Program. Committed to giving back, Thom now serves as Board Member and Vice President of the Suffolk University College of Arts & Sciences Alumni Board of Directors and Advisor on the Sawyer Business School’s Young Alumni Board of Advisors.
Thom resides in Medford, MA.
Outcome Capital and Boston University’s BEST Program Partner to Give Scientists Real-Life Experience in the Life Science Sector June 21, 2017, Boston, MA. Outcome Capital, LLC and Boston University’s BEST program announced today a collaboration aimed at providing young scientists with real-world exposure to business challenges in the life sciences sector. The initiative will be […]Read More
Outcome Capital Announces UCB Pharma Has Acquired Beryllium Discovery June 6, 2017, Boston, MA. Outcome Capital, an investment banking firm that serves middle market growth companies in the life science and technology segments, today announced that UCB Pharma, Ltd. has acquired privately held Beryllium Discovery, LLC. Beryllium, a specialized drug discovery contract research organization (CRO), […]Read More